Metastatic Triple-Negative Breast Cancer (MTNBC) Market is driven by Rising R&D Investments
The metastatic triple-negative breast cancer (MTNBC) treatment market has been witnessing significant growth in the recent years. MTNBC refers to an aggressive type of breast cancer that tests negative for estrogen and progesterone receptors, and lacks excess HER2 protein. Patients of MTNBC have higher chances of disease recurrence and reduced survival rates than other types of breast cancer. Currently, there are no approved targeted therapies for MTNBC and chemotherapy remains the only systemic treatment option. However, researchers and pharmaceutical manufacturers have been focusing on developing novel targeted therapies and immuno-oncology drugs for MTNBC treatment.
The metastatic triple-negative breast cancer (mTNBC) market is estimated to be valued at USD 1.57 Bn in 2024 and is expected to reach USD 2.2 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5% from 2024 to 2031.
North America dominates the global Metastatic Triple-Negative Breast Cancer (MTNBC) Market currently in terms of value. This is due to high per capita healthcare spending led by the United States. Presence of advanced healthcare infrastructure, favorable reimbursement policies, new drug approval process, and increasing adoption of premium-priced targeted therapies and immunotherapies drive the market in the region. Europe ranks second due to public funding of national health services in major countries. However, budget constraints may impact further spending.
Get More Insights On- Metastatic Triple-Negative Breast Cancer (MTNBC) Market
Get This Report in Japanese Language: 転移性トリプルネガティブ乳がん市場
Get This Report in Korean Language: 전이성 삼중 음성 유방암 시장
English
Arabic
Français
Español
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian